ReviewFrontiers in immunology2026
The multifaceted role of NF-κB signaling in psoriasis: from inflammatory amplification to epidermal remodeling.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by persistent epidermal hyperplasia and relapsing inflammation. Although extensive progress has been made in elucidating individual pathogenic pathways, a unifying framework that integrates innate immune activation, adaptive immune maintenance, and keratinocyte-driven amplification remains incomplete. Accumulating evidence indicates that nuclear factor-κB (NF-κB) functions as a central convergence hub that coordinates these diverse inflammatory inputs in psoriasis. In this review, we synthesize recent advances demonstrating how innate immune sensors, including nucleic acid-sensing pathways and Toll-like receptors, converge on NF-κB to initiate inflammatory programs, and how adaptive immune circuits-particularly Th17/IL-17 signaling-exploit NF-κB to sustain disease chronicity. We further highlight the active role of keratinocytes as intrinsic amplifiers of inflammation through NF-κB-dependent programs governing hyperproliferation, oxidative stress responses, and secondary cytokine production. Beyond canonical signaling, emerging evidence reveals that non-coding RNAs and epigenetic regulators fine-tune NF-κB activity, shaping transcriptional persistence and inflammatory memory in psoriatic skin. Finally, we discuss therapeutic strategies targeting the NF-κB convergence hub, including upstream sensor antagonism, adaptor-level modulation, multi-target small molecules, natural products, and advanced skin-targeted delivery systems. By framing NF-κB as a networked regulatory hub rather than a linear pathway, this review provides an integrated perspective on psoriasis pathogenesis and highlights opportunities for precision immunomodulation with improved efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.